Award
National Institute of Allergy and Infectious Diseases 1R41AI191973-01
Investigation of Novel IgY Technology for Fungal Targets in Alcohol-associated Hepatitis
Recipient
PRODIGY BIOTECH, INC.
Award Amount
$314,363.00
Ceiling
$314,363.00
Awarded
September 23, 2025
Identifier
1R41AI191973-01
Award for developing a novel IgY antibody therapy targeting fungal pathogens in alcohol-associated hepatitis, focusing on Candida albicans and candidalysin, funded by NIH.
Description
This project aims to develop a novel IgY antibody-based therapy targeting fungal pathogens in alcohol-associated hepatitis, with a focus on Candida albicans and candidalysin. The project is funded by NIH and involves in vitro and in vivo studies to evaluate efficacy.